Cargando…
Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
Clinical trials showed pangenotypic direct-acting antivirals’ (DAAs) excellent efficacy and safety when treating hepatitis C virus (HCV). Two pangenotypic regimens were examined, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), in a real-world Taiwanese setting, including all...
Autores principales: | Chang, Kao-Chi, Tung, Shui-Yi, Wei, Kuo-Liang, Shen, Chen-Heng, Hsieh, Yung-Yu, Chen, Wei-Ming, Chen, Yi-Hsing, Chen, Chun-Hsien, Yen, Chi-Wei, Xu, Huang-Wei, Tung, Wei-Lin, Hung, Chao-Hung, Lu, Sheng-Nan, Chang, Te-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241842/ https://www.ncbi.nlm.nih.gov/pubmed/34188161 http://dx.doi.org/10.1038/s41598-021-93095-x |
Ejemplares similares
-
Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
por: Huang, Yu-Ting, et al.
Publicado: (2021) -
Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy
por: Chen, Chun-Hsien, et al.
Publicado: (2023) -
Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting
por: Lu, Yung-Hsin, et al.
Publicado: (2022) -
Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis
por: Hsieh, Yung-Yu, et al.
Publicado: (2023) -
Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)